Guardant Shield – the Revolutionary Liquid Biopsy for Colorectal Cancer Screening
Presented by Guardant Health
Monday, March 24, 2025, 3:00 PM – 4:00 PM EST
Today, 1 in 3 eligible adults do not complete recommended colorectal cancer screening because methods can be unpleasant, time-consuming and difficult to complete. Many healthcare organizations struggle to improve screening rates. Most patients prefer a blood test that can be completed at any doctor’s visit. The Shield test from Guardant Health is the first blood-based test approved by the FDA for primary colorectal cancer screening. The FDA approval was based on results of ECLIPSE, a 20,000+-patient registrational study evaluating the performance of the test for detecting CRC in average-risk adults. Shield offers an accurate, easy-to-complete, blood-based approach to cancer screening with the potential to improve screening rates and, ultimately, save more lives.
Julie Wiedower
Senior Director of Medical Affairs
Julie is a certified genetic counselor with over 11 years of experience with genetics services in clinical, laboratory, hospital, and health plan vendor settings. She specialized in utilization management to increase access to appropriate genetic testing across healthcare. She is currently seeking a PhD in Healthcare Genetics from Clemson University studying evidence review frameworks for genomic testing. As Senior Director of Medical Affairs for Guardant Health managed care team, Julie provides expert evidence review of tumor genomic and epigenomic profiling in cancer for health plan audiences. Her passion lies in speaking enthusiastically and effectively to multiple stakeholders while advocating for increased access to quality genetics care and forming partnerships between providers, institutions, health plans, and laboratories.
